What is B. Riley's Estimate for VKTX Q3 Earnings?

Key Points

• Analysts at B. Riley forecast Viking Therapeutics will report Q3 2025 earnings per share of ($0.73), with full-year estimates projecting over ($2.47) EPS for FY2025.
• The stock of Viking Therapeutics has a current market capitalization of $3.04 billion, with an average price target of $86.92 according to analysts.
• Insider transactions revealed CEO Brian Lian sold 26,889 shares on July 3rd, reducing his ownership to approximately $66.39 million worth of stock.

Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) - B. Riley issued their Q3 2025 earnings per share estimates for shares of Viking Therapeutics in a research note issued to investors on Wednesday, August 27th. B. Riley analyst M. Mamtani expects that the biotechnology company will earn ($0.73) per share for the quarter. The consensus estimate for Viking Therapeutics' current full-year earnings is ($1.56) per share. B. Riley also issued estimates for Viking Therapeutics' Q4 2025 earnings at ($0.75) EPS, FY2025 earnings at ($2.47) EPS, FY2026 earnings at ($3.02) EPS, FY2027 earnings at ($3.56) EPS and FY2028 earnings at ($2.80) EPS.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The biotechnology company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.14). During the same period in the prior year, the business earned ($0.20) earnings per share. The business's revenue was up NaN% compared to the same quarter last year.

A number of other brokerages also recently issued reports on VKTX. HC Wainwright reissued a "buy" rating and set a $102.00 price objective on shares of Viking Therapeutics in a research report on Tuesday, August 19th. Citigroup lifted their price objective on Viking Therapeutics from $31.00 to $38.00 and gave the company a "neutral" rating in a research note on Thursday, July 24th. Finally, Raymond James Financial dropped their price objective on Viking Therapeutics from $125.00 to $122.00 and set a "strong-buy" rating for the company in a research note on Thursday, July 24th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $86.92.

Viking Therapeutics Stock Down 2.6%

Shares of VKTX traded down $0.70 during midday trading on Monday, reaching $26.13. The company had a trading volume of 2,149,738 shares, compared to its average volume of 4,772,823. Viking Therapeutics has a 1-year low of $18.92 and a 1-year high of $81.73. The stock has a market cap of $2.94 billion, a PE ratio of -17.08 and a beta of 0.73. The firm has a 50 day simple moving average of $31.24 and a 200-day simple moving average of $28.45.

Insider Buying and Selling

In related news, COO Marianna Mancini sold 4,266 shares of the stock in a transaction on Thursday, July 3rd. The shares were sold at an average price of $27.77, for a total transaction of $118,466.82. Following the completion of the sale, the chief operating officer owned 377,535 shares in the company, valued at $10,484,146.95. This represents a 1.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Brian Lian sold 26,889 shares of the company's stock in a transaction on Thursday, July 3rd. The stock was sold at an average price of $27.80, for a total transaction of $747,514.20. Following the transaction, the chief executive officer owned 2,388,014 shares of the company's stock, valued at approximately $66,386,789.20. The trade was a 1.11% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 35,421 shares of company stock worth $984,405 in the last ninety days. 4.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Viking Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Cambridge Investment Research Advisors Inc. grew its stake in shares of Viking Therapeutics by 121.5% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 29,721 shares of the biotechnology company's stock worth $718,000 after purchasing an additional 16,302 shares during the period. GAMMA Investing LLC increased its holdings in Viking Therapeutics by 9,209.9% in the 1st quarter. GAMMA Investing LLC now owns 24,392 shares of the biotechnology company's stock valued at $589,000 after purchasing an additional 24,130 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Viking Therapeutics in the 4th quarter worth $429,000. Concurrent Investment Advisors LLC acquired a new position in Viking Therapeutics during the 1st quarter worth $220,000. Finally, Parallel Advisors LLC raised its holdings in shares of Viking Therapeutics by 64.8% during the first quarter. Parallel Advisors LLC now owns 1,363 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 536 shares during the period. 76.03% of the stock is owned by institutional investors and hedge funds.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.